C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

• DOI: 10.1161/circulationaha.106.643114
• Publication Date: 2007-02-06T01:51:38Z
• Authors: Naveed Sattar; Heather M. Murray; Alex McConnachie; Gerard J. Blauw; Edward L.E.M. Bollen; Brendan M. Buckley; Stuart M. Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J. Wouter Jukema; Adriaan M. Kamper; Peter W. Macfarlane; Michael B. Murphy; Chris J. Packard; Ivan J. Perry; David J. Stott; Brian J. Sweeney; Cillian Twomey; Rudi G.J. Westendorp; James Shepherd
• Keywords: Stroke; Clinical endpoint

The role of C-reactive protein (CRP) in predicting vascular events and response to statin therapy remains uncertain. Additional large prospective studies are required.Baseline CRP was related risk over 3.2 years for primary a combined end point (definite or suspected death from coronary heart disease, nonfatal myocardial infarction, fatal stroke; n=865 events) secondary (coronary disease stroke alone) tertiary (stroke plus transient ischemic attack) points the Prospective Study Pravastatin Elderly at Risk (n=5804 men women; age, 70 82 years). levels were higher subjects who had subsequent end-point event compared with those did not (geometric mean; 3.64 mg/L [SD, 3.08 mg/L] versus 3.01 3.05 mg/L]; P<0.0001). correlated positively body mass index smoking status negatively high-density lipoprotein cholesterol. unadjusted hazard ratio 1.48 (95% CI, 1.26 1.74) comparison top bottom thirds CRP, falling 1.36 1.15 1.61) adjustment established predictors index. Similar results obtained other when examined separately by history disease. However, baseline added minimally prediction beyond conventional relate magnitude pravastatin benefit.Elevated enhances cardiovascular factors does predict elderly risk. These data suggest that has limited clinical value stratification people.